Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to NKX2-4" (ENSG00000225280, LOC105372558) is a predicted or uncharacterized non-coding RNA transcribed from the DNA strand opposite to the NKX2-4 gene. It is cataloged in public databases for transcriptome completeness but is not known to encode a protein, nor is there published evidence of functional roles, involvement in disease, or use as a biomarker or drug target. Antisense transcripts can theoretically regulate adjacent genes via RNA-based mechanisms, but for ENSG00000225280, such functions have not been established or reported in the literature. The adjacent gene, NKX2-4, is a protein-coding homeobox transcription factor involved in development, but the antisense transcript "novel transcript, antisense to NKX2-4" remains uncharacterized in regard to function, clinical significance, or druggability[4]. The entry is likely retained in genome databases for annotation completeness but does not meet criteria for a structured therapeutic target or canonical molecular family. If you are seeking information about the protein-coding gene NKX2-4 (NK2 homeobox 4), that would be a different, well-annotated target[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to NKX2-4.